Information Provided By:
Fly News Breaks for March 2, 2015
PCYC
Mar 2, 2015 | 07:40 EDT
Leerink raised its price target for Pharmacyclics to $240 citing its M&A valuation after a press report suggested a possible buyout. The firm says its valuation goes as high as $262 per share given the company's liquid tumor opportunities, but its price target of $240 assumes an acquirer gets to keep some of the upside. Leerink keeps an Outperform rating on Pharmacyclics.
News For PCYC From the Last 2 Days
There are no results for your query PCYC
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.